Dala Zakaria

Dala Zakaria


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2014 in Echocardiography
Verified
Journal Article
Closed access
PDF file
DZDala Zakaria
Dala Zakaria
RSRitu Sachdeva
Ritu Sachdeva
JGJeffrey M. Gossett
Jeffrey M. Gossett
XTXinyu Tang
Xinyu Tang
MOMatthew J. O'COnnor
Matthew J. O'COnnor

18 September 2017 in Pediatric Cardiology
Verified
Journal Article
Closed access
PDF file
DZDala Zakaria
Dala Zakaria
XTXinyu Tang
Xinyu Tang
RBRupal Bhakta
Rupal Bhakta
NENahed O. ElHassan
Nahed O. ElHassan
PPParthak Prodhan
Parthak Prodhan

1 November 2016 in Pediatric Cardiology
Verified
Journal Article
Closed access
PDF file
DZDala Zakaria
Dala Zakaria
EFElizabeth Frazier
Elizabeth Frazier
MIMichiaki Imamura
Michiaki Imamura
XGXiomara Garcia
Xiomara Garcia
SPSherry Pye
Sherry Pye
WMW. Robert Morrow
W. Robert Morrow


21 April 2026 in Circulation
Verified
Journal Article
Closed access
TGThomas M. Glenn
Thomas M. Glenn
NKNadine Kasparian
Nadine Kasparian
SAShahnawaz Amdani
Shahnawaz Amdani
DRDavid Renaud
David Renaud
MDMichael V. DiMaria
Michael V. DiMaria
AYAdel K. Younoszai
Adel K. Younoszai
BACKGROUND: Survival after Fontan palliation for single ventricle heart disease has improved substantially, yet the long-term trajectory remains poorly defined. The Fontan Outcomes Network, a learning health network of 38 congenital heart centers in the United States and Canada, was established to address this gap. We report baseline characteristics and early findings from the first 1121 participants enrolled in this prospective clinical registry. METHODS: We performed a cross-sectional analysis of individuals who had undergone Fontan palliation enrolled in the Fontan Outcomes Network from August 2022 through August 2024. Demographic, clinical, imaging, procedural, and medication data were analyzed descriptively, overall and by age group (<12, 12 to <18, and ≥18 years). RESULTS: A total of 1121 participants were enrolled (mean age, 16.3±10.2 years; 471 [42%] female). Hypoplastic left heart syndrome (n=431 [38.5%]) and right ventricular–dominant anatomy (n=615 [54.9%]) were the most common primary cardiac diagnoses, especially in younger age groups. Extracardiac conduit was the most frequent Fontan type (n=749 [66.8%]). Typical Fontan-related adverse events were noted in 59% of cases (n=662), including chylous pleural effusions (n=108 [9.6%]), Fontan thrombosis (n=79 [7.1%]), and nonperioperative stroke (n=73 [6.5%]). A history of arrhythmia was present in 41.3% of patients (n=463) overall, increasing with age. Acquired comorbidities were present in 57.5% of patients (n=645), including asthma (n=132 [12%]) and sleep apnea (n=103 [9%]), with burden increasing by age. Antithrombotic medication use was nearly universal. Use of other medications varied widely by age, and included β-blockers, angiotensin-converting enzyme inhibitors, and pulmonary vasodilators. A clinical diagnosis of an anxiety disorder was present in 34.1% of patients (n=382), including 48.1% of adults (n=194 of 403), and antidepressants were prescribed in 11.8% of patients (n=132), including 23.6% of adults (n=95 of 403), highlighting the mental health needs of this population. CONCLUSIONS: The Fontan Outcomes Network includes one of the largest prospective, multi-institutional data sets of patients with Fontan circulation. These initial findings demonstrate the potential for a collaborative learning health network to advance research and quality improvement for this rare disease population.

29 May 2021 in Pediatric Cardiology
Verified
Journal Article
Closed access
PDF file
LSLaura Schoeneberg
Laura Schoeneberg
PPParthak Prodhan
Parthak Prodhan
BSBeverly Spray
Beverly Spray
Chary AkmyradovChary Akmyradov
Chary Akmyradov
DZDala Zakaria
Dala Zakaria